VANCOUVER, Oct. 8, 2013 /CNW/ - MediJean, a bio-pharmaceutical medical marijuana company, today released details on how the company is leading research and development around medical marijuana in Canada. The company says its R&D plans stem from feedback and interviews with doctors, nurse practitioners and patients across the country who are calling for a scientific approach to medical marijuana.
Being one of the first companies in Canada to receive a research and development exemption from Health Canada that permits it to grow medical marijuana as part of the new Federal Marijuana for Medical Purposes Regulations (MMPR) program has put MediJean on a clear path to lead the industry in this field.
MediJean says their commitment to research and development includes growing the knowledge bank that exists for this important medicine. Currently they have their scientists performing innovative research on the over 200 "building block" cannabis strains that hold the most promise for medical marijuana products. "We believe that through our systematic isolation of genotypes and marrying of diverse strains into products that can be tailored for specific disorders, that we can harness the power and diversity of this remarkable plant, and provide the best possible choices for our patients," said Anton Mattadeen, Chief Strategy Officer at MediJean.
In addition, MediJean will use Gas Chromatograph testing machines that allow them to not only test their own products but all other marijuana that is on the market. Testing is essential to ensure that medical marijuana meets the high standards that patients who need this medicine require.
"Research and development and quality assurance through testing will be key factors that will make MediJean stand out," said Mattadeen. "In our clean-room laboratories our Ph.D. scientists are working on cutting-edge research to increase the knowledge base around cannabis. This will allow us to provide doctors and the medical community with fact-based research on medical marijuana, as well as provide patients with the highest quality product available."
To learn more about how MediJean is moving this industry forward visit http://medijean.com and sign up to receive regular updates.
MediJean is leading the rebirth of medical marijuana through a laser focus on research, quality and patient experience by implementing best practices here and around the world. Doctors and Nurse Practitioners will understand and safely prescribe it within a clinical framework, patients will have access to clean and affordable medicine, and university research partners will help the company expand the frontiers of medical marijuana in the years ahead.
Image with caption: "Dr. Ahad, Ph.D., M.Sc., M.Phil., B.Sc. conducting R&D in one of MediJean's R&D laboratories. (CNW Group/MediJean)". Image available at: http://photos.newswire.ca/images/download/20131008_C8171_PHOTO_EN_31828.jpg